ifosfamide has been researched along with Astrocytoma, Grade IV in 10 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thirty-six patients previously treated with surgery, radiation therapy and chemotherapy with a nitrosourea for malignant supratentorial gliomas received a combination of ifosfamide, carboplatin and etoposide (ICE) at tumour progression." | 9.08 | Treatment of recurrent malignant supratentorial gliomas with ifosfamide, carboplatin and etoposide: a phase II study. ( Ameri, A; Delattre, JY; Monjour, A; Poisson, M; Ronchin, P; Sahmoud, T; Sanson, M, 1996) |
| " The authors report on a 6-year-old girl with a biopsy proven pontine glioblastoma, who, after initial chemo-radiotherapy and tumor progression, experienced a prolonged second response to a salvage therapy consisting of cisplatin, etoposide, and ifosfamide." | 7.71 | Prolonged second response to cisplatin, etoposide, and ifosfamide in a child with a recurrent brainstem glioblastoma. ( Dieckmann, K; Schuller, E; Seidl, R; Slavc, I; Wandl, C, 2001) |
| "Ifosfamide treatment might be a feasible approach, but it necessitates hospitalization." | 6.69 | Chemotherapy in the treatment of recurrent glioblastoma multiforme: ifosfamide versus temozolomide. ( Bamberg, M; Becker, G; Belka, C; Classen, J; Hoffmann, W; Kortmann, RD; Paulsen, F; Weinmann, M, 1999) |
| " In the present analysis, we retrospectively investigated the feasibility and effectiveness of bevacizumab combined with ICE in patients with glioblastoma at second relapse during ICE treatment." | 5.39 | Retrospective analysis of bevacizumab in combination with ifosfamide, carboplatin, and etoposide in patients with second recurrence of glioblastoma. ( Arakawa, Y; Fujimoto, K; Kikuchi, T; Kunieda, T; Miyamoto, S; Mizowaki, T; Murata, D; Takagi, Y; Takahashi, JC, 2013) |
| "Thirty-six patients previously treated with surgery, radiation therapy and chemotherapy with a nitrosourea for malignant supratentorial gliomas received a combination of ifosfamide, carboplatin and etoposide (ICE) at tumour progression." | 5.08 | Treatment of recurrent malignant supratentorial gliomas with ifosfamide, carboplatin and etoposide: a phase II study. ( Ameri, A; Delattre, JY; Monjour, A; Poisson, M; Ronchin, P; Sahmoud, T; Sanson, M, 1996) |
| " The authors report on a 6-year-old girl with a biopsy proven pontine glioblastoma, who, after initial chemo-radiotherapy and tumor progression, experienced a prolonged second response to a salvage therapy consisting of cisplatin, etoposide, and ifosfamide." | 3.71 | Prolonged second response to cisplatin, etoposide, and ifosfamide in a child with a recurrent brainstem glioblastoma. ( Dieckmann, K; Schuller, E; Seidl, R; Slavc, I; Wandl, C, 2001) |
| "Ifosfamide treatment might be a feasible approach, but it necessitates hospitalization." | 2.69 | Chemotherapy in the treatment of recurrent glioblastoma multiforme: ifosfamide versus temozolomide. ( Bamberg, M; Becker, G; Belka, C; Classen, J; Hoffmann, W; Kortmann, RD; Paulsen, F; Weinmann, M, 1999) |
| " In the present analysis, we retrospectively investigated the feasibility and effectiveness of bevacizumab combined with ICE in patients with glioblastoma at second relapse during ICE treatment." | 1.39 | Retrospective analysis of bevacizumab in combination with ifosfamide, carboplatin, and etoposide in patients with second recurrence of glioblastoma. ( Arakawa, Y; Fujimoto, K; Kikuchi, T; Kunieda, T; Miyamoto, S; Mizowaki, T; Murata, D; Takagi, Y; Takahashi, JC, 2013) |
| " It could therefore be used as an important platform for better prediction of drug dosing and schedule towards personalized medicine." | 1.38 | Towards personalized medicine with a three-dimensional micro-scale perfusion-based two-chamber tissue model system. ( Barker, J; Foltz, G; Honkakoski, P; Küblbeck, J; Li, W; Lin, B; Ma, L; Zhang, J; Zhou, C, 2012) |
| "The adverse effects of combination chemotherapy of ifosfamide, cisplatin, and etoposide (ICE) were evaluated in the treatment of various intracranial brain tumors." | 1.36 | [The safety of combination chemotherapy with ifosfamide, cisplatin, and etoposide (ICE): single-institution retrospective review of 108 cases]. ( Kanamori, M; Kumabe, T; Saito, R; Sonoda, Y; Tominaga, T; Yamashita, Y, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (20.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arakawa, Y | 1 |
| Mizowaki, T | 1 |
| Murata, D | 1 |
| Fujimoto, K | 1 |
| Kikuchi, T | 1 |
| Kunieda, T | 1 |
| Takahashi, JC | 1 |
| Takagi, Y | 1 |
| Miyamoto, S | 1 |
| Aoki, T | 1 |
| Mizutani, T | 1 |
| Nojima, K | 1 |
| Takagi, T | 1 |
| Okumura, R | 1 |
| Yuba, Y | 1 |
| Ueba, T | 1 |
| Takahashi, JA | 1 |
| Miyatake, S | 1 |
| Nozaki, K | 1 |
| Taki, W | 1 |
| Matsutani, M | 1 |
| Kanamori, M | 1 |
| Kumabe, T | 1 |
| Saito, R | 1 |
| Yamashita, Y | 1 |
| Sonoda, Y | 1 |
| Tominaga, T | 1 |
| Ma, L | 1 |
| Barker, J | 1 |
| Zhou, C | 1 |
| Li, W | 1 |
| Zhang, J | 1 |
| Lin, B | 1 |
| Foltz, G | 1 |
| Küblbeck, J | 1 |
| Honkakoski, P | 1 |
| van den Bent, MJ | 1 |
| Grisold, W | 1 |
| Frappaz, D | 1 |
| Stupp, R | 1 |
| Desir, JP | 1 |
| Lesimple, T | 1 |
| Dittrich, C | 1 |
| de Jonge, MJ | 1 |
| Brandes, A | 1 |
| Frenay, M | 1 |
| Carpentier, AF | 1 |
| Chollet, P | 1 |
| Oliveira, J | 1 |
| Baron, B | 1 |
| Lacombe, D | 1 |
| Schuessler, M | 1 |
| Fumoleau, P | 1 |
| Leuraud, P | 1 |
| Taillandier, L | 1 |
| Medioni, J | 1 |
| Aguirre-Cruz, L | 1 |
| Crinière, E | 1 |
| Marie, Y | 1 |
| Kujas, M | 1 |
| Golmard, JL | 1 |
| Duprez, A | 1 |
| Delattre, JY | 2 |
| Sanson, M | 2 |
| Poupon, MF | 1 |
| Classen, CF | 1 |
| Warmuth-Metz, M | 1 |
| Papke, K | 1 |
| Trotter, A | 1 |
| Wolff, JE | 1 |
| Wagner, S | 1 |
| Ameri, A | 1 |
| Monjour, A | 1 |
| Sahmoud, T | 1 |
| Ronchin, P | 1 |
| Poisson, M | 1 |
| Paulsen, F | 1 |
| Hoffmann, W | 1 |
| Becker, G | 1 |
| Belka, C | 1 |
| Weinmann, M | 1 |
| Classen, J | 1 |
| Kortmann, RD | 1 |
| Bamberg, M | 1 |
| Schuller, E | 1 |
| Seidl, R | 1 |
| Wandl, C | 1 |
| Dieckmann, K | 1 |
| Slavc, I | 1 |
4 trials available for ifosfamide and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Phase II study of ifosfamide, carboplatin, and etoposide in patients with a first recurrence of glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2010 |
European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Disease-Free Survival; Female; Glioblastoma; Gl | 2003 |
Treatment of recurrent malignant supratentorial gliomas with ifosfamide, carboplatin and etoposide: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Etopo | 1996 |
Chemotherapy in the treatment of recurrent glioblastoma multiforme: ifosfamide versus temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazin | 1999 |
6 other studies available for ifosfamide and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Retrospective analysis of bevacizumab in combination with ifosfamide, carboplatin, and etoposide in patients with second recurrence of glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2013 |
[The safety of combination chemotherapy with ifosfamide, cisplatin, and etoposide (ICE): single-institution retrospective review of 108 cases].
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, | 2010 |
Towards personalized medicine with a three-dimensional micro-scale perfusion-based two-chamber tissue model system.
Topics: Cell Culture Techniques; Cell Line, Tumor; Cell Survival; Cytochrome P-450 CYP3A; Dacarbazine; Diffu | 2012 |
Distinct responses of xenografted gliomas to different alkylating agents are related to histology and genetic alterations.
Topics: Animals; Antineoplastic Agents, Alkylating; Carboplatin; Carmustine; Chromosome Aberrations; Dacarba | 2004 |
Late response to radiochemotherapy in pediatric glioblastoma: report on two patients treated according to HIT-GBM protocols.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Stem Neoplasms; Child; Cisplatin; Combined Mod | 2006 |
Prolonged second response to cisplatin, etoposide, and ifosfamide in a child with a recurrent brainstem glioblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Stem Neoplasms; Child; Cisplatin; Etoposide; F | 2001 |